Detalles de la búsqueda
1.
Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant.
Breast Cancer Res
; 25(1): 103, 2023 08 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-37653397
2.
BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer.
Breast Cancer Res
; 25(1): 71, 2023 06 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-37337299
3.
Effect of physical exercise on cognitive function after chemotherapy in patients with breast cancer: a randomized controlled trial (PAM study).
Breast Cancer Res
; 24(1): 36, 2022 05 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-35619188
4.
Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial.
Ann Oncol
; 33(10): 1021-1028, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35772665
5.
Concurrent chemo-endocrine treatment for early hormone-positive breast cancer: a no-go???
Breast Cancer Res Treat
; 192(3): 485-489, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-35132502
6.
Peroperative extent of peritoneal metastases affects the surgical outcome and survival in advanced ovarian cancer.
Gynecol Oncol
; 167(2): 269-276, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36088169
7.
Efficacy and safety of durvalumab with olaparib in metastatic or recurrent endometrial cancer (phase II DOMEC trial).
Gynecol Oncol
; 165(2): 223-229, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35287967
8.
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival.
Ann Oncol
; 32(8): 1015-1024, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34102253
9.
Cardiotoxicity during long-term trastuzumab use in patients with HER2-positive metastatic breast cancer: who needs cardiac monitoring?
Breast Cancer Res Treat
; 186(3): 851-862, 2021 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-33394273
10.
Toward omitting sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with clinically node-negative breast cancer.
Br J Surg
; 108(6): 667-674, 2021 06 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-34157085
11.
Feasibility and outcomes of a goal-directed physical therapy program for patients with metastatic breast cancer.
Support Care Cancer
; 29(6): 3287-3298, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-33104921
12.
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.
Ann Oncol
; 30(7): 1080-1087, 2019 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31046082
13.
Radiological complete remission in HER2-positive metastatic breast cancer patients: what to do with trastuzumab?
Breast Cancer Res Treat
; 178(3): 597-605, 2019 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-31493033
14.
Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib.
BMC Cancer
; 19(1): 901, 2019 Sep 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31500595
15.
The prognostic value of residual disease after neoadjuvant chemotherapy in advanced ovarian cancer; A systematic review.
Gynecol Oncol
; 153(2): 445-451, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30826010
16.
The effect of adjuvant chemotherapy on survival in patients with FIGO stage I high-grade serous ovarian cancer.
Gynecol Oncol
; 153(3): 562-567, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30948193
17.
Physical problems, functional limitations, and preferences for physical therapist-guided exercise programs among Dutch patients with metastatic breast cancer: a mixed methods study.
Support Care Cancer
; 27(8): 3061-3070, 2019 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-30610432
18.
Localization of distant metastases defines prognosis and treatment efficacy in patients with FIGO stage IV ovarian cancer.
Int J Gynecol Cancer
; 29(2): 392-397, 2019 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-30665898
19.
Patient-centered, self-funding dose optimization trials as a route to reduce toxicity, lower cost, and improve access to cancer therapy.
Ann Oncol
; 34(8): 638-644, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37230253
20.
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
Ann Oncol
; 29(7): 1541-1547, 2018 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29718092